Table 3 Kaplan–Meier and Cox regression analysis of survival and time to progression data
Control ( n =613) | Epoetin beta ( n =800) | ||||||
|---|---|---|---|---|---|---|---|
Patient group | Total events | Mean patient-years of follow-up | Events per patient-year | Total events | Mean patient-years of follow-up | Events per patient-year | Hazard ratio (95% CI) |
Overall survival | |||||||
Total | 58 | 0.30 | 0.32 | 80 | 0.32 | 0.31 | 0.97 (0.69–1.36) |
Tumour type | |||||||
Solid | 17 | 0.25 | 0.24 | 22 | 0.32 | 0.21 | 0.94 (0.50–1.78) |
Haematological | 41 | 0.34 | 0.37 | 58 | 0.32 | 0.39 | 1.04 (0.69–1.55) |
Time to progression | |||||||
Total | 133 | 0.27 | 0.81 | 145 | 0.29 | 0.62 | 0.78 (0.62–0.99) |
Tumour type | |||||||
Solid | 50 | 0.23 | 0.78 | 50 | 0.30 | 0.50 | 0.71 (0.48–1.06) |
Haematological | 82 | 0.31 | 0.81 | 93 | 0.29 | 0.69 | 0.84 (0.62–1.13) |
